Skip to main content
NCBI home page
Oncology Letters logoLink to Oncology Letters
. 2016 Nov 7;12(6):5247–5253. doi: 10.3892/ol.2016.5355

miR-574-3p acts as a tumor promoter in osteosarcoma by targeting SMAD4 signaling pathway

Haidong Xu 1,*, Xiaozhou Liu 1,*, Juan Zhou 1, Xiaoyun Chen 1, Jianning Zhao 1,✉
PMCID: PMC5228465  PMID: 28105233

Abstract

Human osteosarcoma is the most common primary bone malignancy sarcoma that affects primarily children and people <20 years old. In the present study, it was demonstrated that miR-574-3p was downregulated in human osteosarcoma U2OS, SAOS and MG63 cells lines as well as in osteosarcoma tissue compared with the normal tissues. Downregulation of miR-574-3p by antisense miR-574-3p, inhibited cell growth and induced cell apoptosis. Overexpression of miR-574-3p by transfection with miR-574-3p mimics promoted the growth of U2OS cells. The present study then identified mothers against decapentaplegic homolog 4 (SMAD4) as a target of miR-574-3p and SMAD4 was suppressed in miR-574-3p transfected cells. Overexpression of SMAD4 could rescue the promoting effects of miR-574-3p on cancer cell growth. In conclusion, miR-574-3p exerts tumor-promoting roles by targeting the tumor-suppressing gene SMAD4 and its downstream signaling in human osteosarcoma, which provides a novel target for the treatment.

Keywords: osteosarcoma, miR-574-3p, oncogene, SMAD4

Introduction

Human osteosarcoma is the most common primary bone malignancy sarcoma found primarily in children and young people (1–3). The patients with osteosarcoma exhibit severe clinical manifestations, significantly diminished mobility and a reduced life expectancy (4,5). However, the prognosis remained poor. It is important to clarify the underlying mechanism so that safe and effective therapeutic strategies may be developed.

MicroRNA (miRNA) is a class of small non-coding RNA, with lengths of 18–22 nucleotides; they play important roles in numerous biological processes through transcriptional suppression of target genes (6–8). The critical functions of numerous miRNAs in cancer biology have been illustrated, including the regulation of various cellular processes, such as proliferation and apoptosis (3,5,9,10). The abnormality of miR-574-3p was observed in patients with non-small cell lung cancer and prostate cancer, and it was found that this miRNA regulated colorectal cancer growth and plays important roles in bladder cancer cell lines (11–13). Nevertheless, whether miR-574-3p participates in the progression of osteosarcoma remains unclear. In the present study, it was demonstrated that the level of miR-574-3p was significantly higher in the human osteosarcoma tissues and cell lines and miR-574-3p also regulated osteosarcoma cell growth through targeting the mothers against decapentaplegic homolog 4 (SMAD4) signaling pathway.

Materials and methods

Patients

Surgical specimens from 10 osteosarcoma and matched normal control tissues were obtained postoperatively in May 2010 from the Department of Orthopedics of Jinling Hospital, Nanjing University, School of Medicine (Nanjing, China) (3,5,10). All patients provided signed informed consent for their tissues to be used for scientific research. Ethical approval for the study was obtained from Jinling Hospital, Nanjing University. All diagnoses were based on pathological and/or cytological evidence (10). The histological features of the specimens were evaluated by senior pathologists according to the World Health Organization classification criteria (11–13). Tissues were obtained prior to chemotherapy and radiotherapy, and were immediately frozen and stored at −80°C prior to reverse-transcription quantitative polymerase chain reaction (RT-qPCR) assay (3,5,10).

Cell lines, cell culture and transfection

Human osteosarcoma U2OS, SAOS and MG63 cell lines, and the normal human osteoblast cell line were obtained from Jinling Hospital Affiliated to Nanjing University (Nanjing, China), and maintained in Dulbecco's Modified Eagle's medium supplemented with 10% fetal bovine serum (GE Healthcare Bio-Sciences- Pittsburgh, PA, USA) (10). U2OS and MG63 cells were seeded in 24-well plates at a density of 6×104 cells per well and transfected with antisense (ASO)-miR574, mimics (Shanghai GenePharma Co., Ltd., Shanghai, China) or pcDNA3.1-SMAD4 at a concentration of 50 nM using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc., Pittsburgh, PA, USA) according to the manufacturer's protocol. Subsequent to 48 h, cells were used for additional experiments (3).

RNA extraction and RT-qPCR

RNA from tumor tissues of differently treated groups were homogenized in TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) and isolated according to the manufacturer's protocol. RT-qPCR was assessed using the miScript RT Kit and miScript PCR system (both Qiagen China Co., Ltd., Shanghai, China) according to the manufacturer's protocol, during which glyceraldehyde 3-phosphate dehydrogenase was used as an internal control (3). The thermocycling conditions for the PCR were was as follows: 95°C for 15 min; 40 cycles of 94°C for 15 sec, 55°C for 30 sec and 70°C for 30 sec; and 95°C for 1 min (3–5). Data were normalized using the 2−ΔΔCq method, whereby the cycle threshold (Cq) for the gene of interest was compared with the Cq of the internal control gene (14).

Western blot assay

Cells were homogenized in Mammalian Protein Extraction reagent containing a Halt Protease Inhibitor Cocktail (both Thermo Fisher Scientific, Inc.), 150 mM NaCl and 1 mM EDTA. The lysates were mixed with an equal volume of sample buffer (cat. no. P0015B; Beyotime Institute of Biotechnology, Haimen, China) and proteins were subsequently denatured by boiling. Protein quantification was performed using an Enhanced BCA Protein Assay kit (cat. no. P0010S; Beyotime Institute of Biotechnology). A total of 20 µg protein was loaded into each lane. Total protein was separated using SDS-PAGE on a 10% gel (3). The proteins were transferred onto nitrocellulose membranes (GE Healthcare Life Sciences, Chalfont, UK), blocked with 5% milk and incubated overnight at 4°C with the primary antibody anti-SMAD4 (1:1,500; cat. no. ab40759; Abcam, Cambridge, UK); β-actin was used as the loading control (anti-β-actin; 1:13,000; cat. no. ab8227; Abcam). The blots were then incubated with the anti-rabbit immunoglobulin G horseradish peroxidase-conjugated secondary antibody (1:10,000; cat. no. ab7090; Abcam) for 1 h at room temperature. Immunoreactivity was detected using the ImageQuant™ LAS-4000 Luminescent Image Analyzer (GE Healthcare Life Sciences). Protein bands were quantified by means of densitometry using Fuji Image Gauge software (version 4.0; Fujifilm) as previously described (3).

Proliferation assay

Cells were seeded into 96-well plates at a density of 4,000 cells per well and transfected with miR-574-3p/negative control/pcDNA3.1-SMAD4 (3,5,10). Cell viability was determined by methyl thiazolyl tetrazolium (MTT) assay to detect the viable proliferating cells at different time points subsequent to transfection (3). The MTT Cell Proliferation and Cytotoxicity assay kit (Amresco, LLC, Solon, OH, USA) was used. Following photosensitization, 100 µg MTT in 20 µl PBS was added to each well at 0, 24, 48 and 72 h and plates were subsequently incubated at 37°C for 3 h. The reaction was stopped by the addition of 180 µl dimethyl sulfoxide. The optical density (OD) of each sample was subsequently measured at a wavelength of 490 nm using a microplate spectrophotometer (Thermo 3001; Thermo Fisher Scientific, Inc.). Cell survival rate (%) was calculated as the following: (ODtreated / ODcontrol) × 100.

Apoptosis assay

Following transfection of the U2OS and MG-63 cells with the miR-574-3p ASO, miR-574-3p mimics or controls. Cell apoptosis was determined using apoptosis detection kit (Beyotime Institute of Biotechnology) according to the manufacturer's protocol (3,5,10). Samples were determined by flow cytometry assays and the results were analyzed using Cell-Quest software (version 7.5.3; Becton Dickinson, San Jose, CA, USA).

miRNA target prediction and luciferase assay

miRNA targets were predicted using the TargetScan algorithms (http://www.targetscan.org). The SMAD4-luciferase-3′-untranslated region (UTR) reporter was generated by inserting the full length SMAD4 3′-UTR into pGL3 promoter vector (Promega Corporation, Madison, WI, USA) as previously reported (3). Luciferase assays were performed using NIH3T3 cells, as previously described (15). Cells were transfected with appropriate plasmids [TK Renilla luciferase (RL) plasmids, wild type or mutated SMAD4 3′-UTR pGL3 promoter vector, synthetic miR mimics/inhibitors (ASO oligo) with scramble control] in 24-well plates. Cells were lysed for the luciferase assay 48 h subsequent to transfection. Luciferase assays were conducted by using a luciferase assay kit (E1910; Promega Corporation) according to the manufacturer's protocol (3,5,10).

Statistical analysis

The data was expressed as the mean ± standard deviation. Student's t-test was used for comparisons between experimental groups and relevant controls (3,5). The difference between groups was analyzed using one-way analysis of variance when ≥3 groups were compared. P<0.05 was considered to indicate a statistically significant difference. The correlation between SMAD4 protein and miR-574-3p expression levels was assessed by Spearman's rank correlation coefficient analysis.

Results

miR-574 level was elevated in human osteosarcoma tissues

Initially, the present study assessed the levels of miR-574-3p in U2OS, SAOS2 and MG63 osteosarcoma cell lines by RT-qPCR; the miR-574-3p level in osteoblast cells was used as a control. It was found that the expression levels of miR-574-3p in the 3 osteosarcoma cell lines were significantly higher than that in osteoblast cells (P=0.0023; Fig. 1A). The miR-574-3p levels in 10 pairs of human osteosarcoma tissues and the matched tumor adjacent normal tissues were assayed by RT-qPCR. It was found that osteosarcoma tissues showed a significantly higher level of miR-574-3p than the matched tumor-adjacent normal tissues in all 10 pairs (P=0.0089; Fig. 1B).

Figure 1.

Figure 1.

Open in a new tab

Increased levels of miR-574-3p in osteosarcoma tissues and cell lines. (A) The miR-574-3p levels in h-OB, U2OS, Saos-2 and MG-63 cells were analyzed by RT-qPCR. The miR-574-3p level in h-OB was arbitrarily defined as 100%. The miR-574-3p expressions in 10 pairs of osteosarcoma and in matched tumor-adjacent normal tissue specimens were analyzed by RT-qPCR. (A) The miR-574-3p levels in in matched tumor-adjacent normal tissues were arbitrarily defined as 100%. Bar graphs of increased levels of miR-574-3p in (A) human osteosarcoma cell lines and (B) paired human osteosarcoma tissues. All RT-qPCR experiments where repeated three times. Data are mean ± SD with experiments repeated three times. *P<0.05 vs. corresponding wild-type cells. miR, microRNA; h-OB, human osteoblast; RT-qPCR, reverse-transcription-quantitative polymerase chain reaction.

Downregulation of miR-574-3p inhibited cell growth and induced cell apoptosis

To investigate the effects of miR-574-3p on osteosarcoma cells, miR-574-3p levels were inhibited in U2OS and MG-63 cells by transfecting the cells with miR-574-3p ASO. The miR-574-3p levels in cells were assessed by RT-qPCR 48 h subsequent to transfection. It was found that miR-574-3p ASO significantly inhibited the miR-574-3p levels in the two cell lines (P=0.0073; Fig. 2A). Following transfection, cellular proliferation was then assessed by MTT analysis. The data suggested that knockdown of miR-574-3p significantly inhibited the growth of U2OS and MG63 cells (P=0.0102; Fig. 2B). Fluorescence-activated cell sorting (FACS) analysis showed that the inhibition of miR-574-3p induced cell apoptosis in MG63 and U2OS cells (Fig. 2C).

Figure 2.

Figure 2.

Open in a new tab

Suppression of miR-574-3p inhibited the cellular proliferation of and induced cells apoptosis of U2OS and MG63 cells. U2OS and MG-63 cells were transfected with miR-574-3p ASO. 48 h later miR-574-3p level in U2OS and MG-63 cells was assayed by RT-qPCR. (A) The miR-574-3p level in the blank control was arbitrarily defined as 100%. (B) Following miR-574-3p ASO transfection, the proliferation of U2OS and MG-63 cells was analyzed by MTT at the indicated time point. (C) Subsequent to 48 h following miR-574-3p ASO transfection, apoptosis of U2OS and MG-63 cells was assessed by FACS analysis. All data are expressed as the mean ± SD, with experiments repeated three times. *P<0.05. miR, microRNA; ASO, antisense; O.D., optical density; RT-qPCR, reverse-transcription quantitative polymerase chain reaction; MTT, methyl thiazolyl tetrazolium, FACS, fluorescence-activated cell sorting.

Overexpression of miR-574-3p promoted cells growth

The level of miR-574-3p levels in U2OS cells was overexpressed by transfection of miR-574-3p mimics. The miR-574-3p levels in U2OS cells were assessed by RT-qPCR 48 h after transfection. The miR-574-3p level in U2OS cells was significantly overexpressed by miR-574-3p transfection with mimics (P=0.0093; Fig. 3A). The cellular proliferation was then examined by MTT analysis following miR-574-3p mimic transfection. The overexpression of miR-574-3p significantly promoted the cellular proliferation of U2OS (P=0.0115; Fig. 3B).

Figure 3.

Figure 3.

Open in a new tab

miR-574-3p mimics promoted cell growth in U2OS cells. U2OS cells were transfected with miR-574-3p mimics. The miR-574-3p level in U2OS cells was assessed by RT-qPCR 48 h later. (A) miR-574-3p level in blank control was arbitrarily defined as 100%. (B) Following miR-574-3p mimics transfection, the proliferation of U2OS cells was analyzed by MTT at the time points 0, 24, 48 and 72 h. All data are expressed as the mean ± standard deviation with experiments repeated three times. *P<0.05. miR, microRNA; RT-qPCR, reverse-transcription quantitative polymerase chain reaction.

miR-574-3p directly targets the SMAD4 signaling pathway

To identify the potential targeted genes, SMAD4 was predicted as a target gene of miR-574-3p by using TargetScan. SMAD4 is a unique common effector of tumor growth factor-β (TGF-β) and bone morphogenetic protein signal pathways (16). SMAD4 is frequently mutated in human carcinomas, leading to loss of growth inhibition by TGF-β (17). Thus, SMAD4 was chosen for additional investigation. The 3′untranslated region (3′-UTR) and mutant 3′-UTR of SMAD4 were used for the identification of target gene of miR-574-3p (Fig. 4A). It was found that miR-574-3p could markedly decrease the luciferase activity in SMAD4 3′-UTR transfected cells while not in the mutant-transfected cells (Fig. 4B). U2OS cells were then transfected with miR-574-3p mimics. SMAD4 protein level was then assessed by western blotting after 48 h. It was found that SMAD4 expression was also significantly inhibited in miR-574-3p-expressing cells (P=0.0079; Fig. 4C). Cyclin-dependent kinase inhibitor 1 (CDKN1A), cyclin dependent kinase 4 inhibitor B (CDKN2B) and inhibitor of DNA binding (ID3) are the SMAD4-dependent genes (18). The present data showed that CDKN1A, CDKN2B and ID3 were also significantly repressed in U2OS cells by transfection with miR-574-3p mimics compared with the negative control miRNA-transfected cells (P=0.0068; Fig. 4D).

Figure 4.

Figure 4.

Open in a new tab

SMAD4 was targeted by miR-574-3p. Putative targeted genes were predicted by TargetScanHuman. (A) The binding site of putative targeted gene, and mutated site of miR-574-3p are shown. The RL reporter plasmids (RL-control, RL-SMAD4, RL-mutated SMAD4) and miR-574-3p or miR-NC were co-transfected into HEK293 cells, along with a firefly luciferase reporter (pGL control) for normalization. (B) Luciferase activities were determined following 48 h. The ratio of pGL activity vs. RL luciferase activity in the miR-574-3p treated group was then calculated and compared with the ratio in the miR-NC group (which was arbitrarily defined as 100%). (C) Subsequent to 60 h after transfection with miR-574-3p mimics SMAD4 protein levels were assessed by western blotting. (D) Then, 60 h after transfection with miR-574-3p mimics, the CDKN1A, CDKN2B and ID3 mRNA levels in U2OS cells were assessed by RT-qPCR. All data are expressed as the mean ± standard deviation, with experiments repeated three times. *P<0.05. miR, microRNA; SMAD4, mothers against decapentaplegic homolog 4; RL, Renilla luciferase; NC, negative control; CDKN1A, cyclin-dependent kinase inhibitor 1; CDKN2B, cyclin dependent kinase 4 inhibitor B; ID3, inhibitor of DNA binding; RT-qPCR, reverse-transcription quantitative polymerase chain reaction; WT, wild type; Mut, mutant.

Overexpression of SMAD4 attenuated the tumor promoting effects of miR-574-3p

The SMAD4 levels were investigated in osteosarcoma tissues by RT-qPCR. It was found that osteosarcoma tissues showed significantly decreased SMAD4 mRNA expression compared with adjacent normal tissues (P=0.0058; Fig. 5A). Subsequently, the miR-574-3p levels and the SMAD4 levels in 10 osteosarcoma tissue samples were analyzed, and it was found that the miR-574-3p levels and the SMAD4 levels were negatively correlated (Fig. 5B). By RT-qPCR, the expression of SMAD4 target genes, CDKN1A, CDKN2B and ID2, were also significantly decreased in osteosarcoma tissues (P=0.0093; Fig. 5C). U2OS cell were co-transfected with SMAD4 overexpression plasmid, pc3.1-SMAD4 and miR-574-3p mimics. The cell growth was evaluated by MTT analysis 48 h later. It was found that that the tumor-promoting effect of miR-574-3p was significantly inhibited by overexpression of SMAD4 (P=0.0124; Fig. 5D).

Figure 5.

Figure 5.

Open in a new tab

miR-574-3p was negatively correlated with the SMAD4 signaling pathway and overexpression of SMAD4 attenuated the tumor promoting effects of miR-574-3p. In total, 10 pairs of osteosarcoma and matched tumor-adjacent normal tissues were analyzed by RT-qPCR for SMAD4 mRNA. (A) The mean level of SMAD4 mRNA in tumor-adjacent normal tissues was arbitrarily defined as 100%. (B) The correlation between SMAD4 mRNA and miR-574-3p levels in the 10 osteosarcoma tissues was analyzed by two-tailed Spearman's rank correlation coefficient analysis. (C) The CDKN1A, CDKN2B and ID3 mRNA levels in 10 pairs of osteosarcoma and matched tumor-adjacent normal tissues were analyzed by RT-qPCR. The CDKN1A, CDKN2B and ID3 mRNA levels in tumor-adjacent normal tissues were arbitrarily defined as 100%. U2OS cells were co-transfected with pcDNA3.1-SMAD4 and miR-574-3p mimics; pcDNA3.1 empty plasmid and miR-NC were used as controls. (D) The relative cell numbers were determined by MTT analysis 48 h subsequent to transfection. The relative cell number in miR-NC and pcDNA3.1 empty plasmid was arbitrarily defined as 100%. All data are mean ± standard deviation with experiments repeated three times. *P<0.05. miR, microRNA; NC, negative control; SMAD4, mothers against decapentaplegic homolog 4; RT-qPCR, reverse-transcription quantitative polymerase chain reaction; CDKN1A, cyclin-dependent kinase inhibitor 1; CDKN2B, cyclin dependent kinase 4 inhibitor B; ID3, inhibitor of DNA binding; N, normal; T, tumor.

Discussion

miR-574 has been found to be upregulated in several types of cancers, including lung cancer, bladder cancer and prostate cancer (11–13,19). Foss et al (17) also suggested miR-574 as a serum biomarker of non-small cell lung cancer. miR-574-3p negatively regulates Quaking 6/7 (Qki6/7), thus affecting β-catenin/wingless (Wnt) signaling and the development of colorectal cancer (12). Furthermore, miR-574-3p was associated with various human cancers (19,20). In the present study, it was demonstrated that miR-574-3p was downregulated in human osteosarcoma tissues as well as osteosarcoma U2OS, SAOS and MG63 cell lines. Inhibition of miR-574-3p by ASO attenuated cell proliferation and resulted in the apoptosis in osteosarcoma cells, while miR-574-3p mimics promoted the growth of U2OS cells. Subsequently, SMAD4 was identified as a target of miR-574-3p. SMAD4 overexpression could rescue the promoting effects of miR-574-3p on cancer cell growth, which additionally supports the theory that miR-574-3p may be associated with SMAD4.

miRNAs are critical regulators and biomarkers for numerous types of cancers (8,21–24). There are several miRNAs that have been found to be abnormal in human osteosarcoma, including miR-141, miR-429, miR-451, miR-195, miR-183 miR-199a-3p, miR-127-3p and miR-376c (3,5,10,25–27). In the present study, it was reported that miR-574-3p was highly expressed in human osteosarcoma cells lines and tissues, and it was indicated that miR-574-3p may be used as a biomarker for the diagnosis of osteosarcoma.

The present study observed that miR-574-3p is closely and positively associated with the proliferation of osteosarcoma cells. Downregulation of miR-574-3p suppressed the growth of U2OS cells and MG63 cells with the induction of apoptosis, while overexpression of miR-574-3p enhanced the growth of these cells. These data indicated that miR-574-3p plays an oncogene-like function in osteosarcoma development. It has been also reported that miR-574-3p targets Qki6/7 and affects colorectal cancer through acting on the Wnt signaling pathway (12). In the present study, it was suggested that SMAD4 is a direct target of miR-574-3p and the associated genes CDKN1A, CDKN2B as well as ID3 were strongly suppressed by miR-574-3p transfection. SMAD4 is often mutated in numerous cancers and it acts as a tumor suppressor that is involved in the regulation of the TGF-β signal transduction pathway, which negatively regulates growth of epithelial cells and the extracellular matrix (28–31). Therefore, the inhibition of SMAD4 and its downstream proteins may be an important part of the mechanism of miR-574-3p in osteosarcoma.

To investigate the importance of miR-574-3p-SMAD4 interaction in osteosarcoma, the current study determined the level of SMAD4 and its associated genes (CDKN1A, CDKN2B and ID2) and found that they were all decreased in osteosarcoma tissues. The expression of miR-574-3p was inversely correlated with SMAD4 expression. Notably, SMAD4 overexpression rescued the tumor-promoting effects of miR-574-3p, indicating that miR-574-3p exerted an oncogenic effect, mainly through regulating the SMAD4 signaling pathway. However, a single miRNA could modulate >100 target genes (6), and the underlying mechanism continues to require clarification in future studies.

In conclusion, the present study found that that miR-574-3p is upregulated in human osteosarcoma, and plays an oncogene-like role in human osteosarcoma through targeting the tumor-suppressing gene SMAD4 and acting on the SMAD4 signaling pathway. The current findings provide a novel target for the diagnosis and treatment of human osteosarcoma.

References

  • 1.de Oliveira JM Ferreira, Remédios C, Oliveira H, Pinto P, Pinho F, Pinho S, Costa M, Santos C. Sulforaphane induces Dna damage and mitotic abnormalities in human osteosarcoma mg-63 cells: Correlation with cell cycle arrest and apoptosis. Nutr Cancer. 2014;66:325–334. doi: 10.1080/01635581.2014.864777. [DOI] [PubMed] [Google Scholar]
  • 2.Walter I, Wolfesberger B, Miller I, Mair G, Burger S, Gallè B, Steinborn R. Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS. Oncol Rep. 2014;31:1147–1156. doi: 10.3892/or.2013.2954. [DOI] [PubMed] [Google Scholar]
  • 3.Xu H, Mei Q, Shi L, Lu J, Zhao J, Fu Q. Tumor-Suppressing effects of miR451 in human osteosarcoma. Cell Biochem Biophys. 2014;69:163–168. doi: 10.1007/s12013-013-9801-7. [DOI] [PubMed] [Google Scholar]
  • 4.Li R, Zhang W, Cui J, Shui W, Yin L, Wang Y, Zhang H, Wang N, Wu N, Nan G, et al. Targeting BMP9-promoted human osteosarcoma growth by inactivation of notch signaling. Curr Cancer Drug Targets. 2014;14:274–285. doi: 10.2174/1568009614666140305105805. [DOI] [PubMed] [Google Scholar]
  • 5.Liu X, Liu Y, Wu S, Shi X, Li L, Zhao J, Xu H. Tumor-suppressing effects of mir-429 on human osteosarcoma. Cell Biochem Biophys. 2014;70:215–224. doi: 10.1007/s12013-014-9885-8. [DOI] [PubMed] [Google Scholar]
  • 6.Chu Y, Zhu H, Lv L, Zhou Y, Huo J. MiRNA s in oesophageal squamous cancer. Neth J Med. 2013;71:69–75. [PubMed] [Google Scholar]
  • 7.Lai X, Wolkenhauer O, Vera J. Modeling miRNA regulation in cancer signaling systems: miR-34a regulation of the p53/Sirt1 signaling module. Methods Mol Biol. 2012;880:87–108. doi: 10.1007/978-1-61779-833-7_6. [DOI] [PubMed] [Google Scholar]
  • 8.Mo MH, Chen L, Fu Y, Wang W, Fu SW. Cell-free circulating miRNA biomarkers in cancer. J Cancer. 2012;3:432–448. doi: 10.7150/jca.4919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ahmed FE. miRNA as markers for the diagnostic screening of colon cancer. Expert Rev Anticancer Ther. 2014;14:463–485. doi: 10.1586/14737140.2014.869479. [DOI] [PubMed] [Google Scholar]
  • 10.Xu H, Mei Q, Xiong C, Zhao J. Tumor-suppressing effects of miR-141 in human osteosarcoma. Cell Biochem Biophys. 2014;69:319–325. doi: 10.1007/s12013-013-9801-7. [DOI] [PubMed] [Google Scholar]
  • 11.Xu H, Liu X, Zhao J. Down-regulation of miR-3928 promoted osteosarcoma growth. Cell Physiol Biochem. 2014;33:1547–1556. doi: 10.1159/000358718. [DOI] [PubMed] [Google Scholar]
  • 12.Liu X, Liu Y, Wu S, Shi X, Li L, Zhao J, Xu H. Tumor-suppressing effects of miR-429 on human osteosarcoma. Cell Biochem Biophys. 2014;70:215–224. doi: 10.1007/s12013-014-9885-8. [DOI] [PubMed] [Google Scholar]
  • 13.Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014;105:755–762. doi: 10.1111/cas.12436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
  • 15.Chiyomaru T, Yamamura S, Fukuhara S, Hidaka H, Majid S, Saini S, Arora S, Deng G, Shahryari V, Chang I, et al. Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer. PLoS One. 2013;8:e58929. doi: 10.1371/journal.pone.0058929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ji S, Ye G, Zhang J, Wang L, Wang T, Wang Z, Zhang T, Wang G, Guo Z, Luo Y, et al. miR-574-5p negatively regulates Qki6/7 to impact β-catenin/Wnt signalling and the development of colorectal cancer. Gut. 2013;62:716–726. doi: 10.1136/gutjnl-2011-301083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: Serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol. 2011;6:482–488. doi: 10.1097/JTO.0b013e318208c785. [DOI] [PubMed] [Google Scholar]
  • 18.Cui J, Cheng Y, Zhang P, Sun M, Gao F, Liu C, Cai J. down regulation of miR200c promotes radiation-induced thymic lymphoma by targeting BMI1. J Cell Biochem. 2014;115:1033–1042. doi: 10.1002/jcb.24754. [DOI] [PubMed] [Google Scholar]
  • 19.Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685–700. doi: 10.1016/S0092-8674(03)00432-X. [DOI] [PubMed] [Google Scholar]
  • 20.Schutte M. DPC4/SMAD4 gene alterations in human cancer, and their functional implications. Ann Oncol. 1999;10:56–59. doi: 10.1093/annonc/10.suppl_4.S56. (Suppl 4) [DOI] [PubMed] [Google Scholar]
  • 21.Kowanetz M, Valcourt U, Bergström R, Heldin CH, Moustakas A. Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol. 2004;24:4241–4254. doi: 10.1128/MCB.24.10.4241-4254.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Su Y, Ni Z, Wang G, Cui J, Wei C, Wang J, Yang Q, Xu Y, Li F. Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p. Int Immunopharmacol. 2012;13:468–475. doi: 10.1016/j.intimp.2012.05.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Meyers-Needham M, Ponnusamy S, Gencer S, Jiang W, Thomas RJ, Senkal CE, Ogretmen B. Concerted functions of HDAC1 and microRNA-574-5p repress alternatively spliced ceramide synthase 1 expression in human cancer cells. EMBO Mol Med. 2012;4:78–92. doi: 10.1002/emmm.201100189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Chen Y, Sun Y, Chen L, Xu X, Zhang X, Wang B, Min L, Liu W. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep. 2013;7:1579–1584. doi: 10.3892/mmr.2013.1403. [DOI] [PubMed] [Google Scholar]
  • 25.Sun D, Layer R, Mueller AC, Cichewicz MA, Negishi M, Paschal BM, Dutta A. Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells. Oncogene. 2014;33:1448–1457. doi: 10.1038/onc.2013.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Martin EC, Bratton MR, Zhu Y, Rhodes LV, Tilghman SL, Collins-Burow BM, Burow ME. Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line. PLoS One. 2012;7:e49067. doi: 10.1371/journal.pone.0049067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B, Amsellem-Ouazana D, Bieche I. microRNA expression profile in a large series of bladder tumors: Identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer. 2013;132:2479–2491. doi: 10.1002/ijc.27949. [DOI] [PubMed] [Google Scholar]
  • 28.Ouyang L, Liu P, Yang S, Ye S, Xu W, Liu X. A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma. Med Oncol. 2013;30:340. doi: 10.1007/s12032-012-0340-7. [DOI] [PubMed] [Google Scholar]
  • 29.Novello C, Pazzaglia L, Cingolani C, Conti A, Quattrini I, Manara MC, Tognon M, Picci P, Benassi MS. miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol. 2013;42:667–675. doi: 10.3892/ijo.2012.1717. [DOI] [PubMed] [Google Scholar]
  • 30.Maire G, Martin JW, Yoshimoto M, Chilton-MacNeill S, Zielenska M, Squire JA. Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet. 2011;204:138–146. doi: 10.1016/j.cancergen.2010.12.012. [DOI] [PubMed] [Google Scholar]
  • 31.Xue J, Lin X, Chiu WT, Chen YH, Yu G, Liu M, Feng XH, Sawaya R, Medema RH, Hung MC, Huang S. Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis. J Clin Invest. 2014;124:564–579. doi: 10.1172/JCI71104. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Oncology Letters are provided here courtesy of Spandidos Publications

RESOURCES